Meditope-Enabled CAR T Cells for Universal Antibody Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR T-cell therapies require the creation of new genes to change target specificity, limiting their versatility and efficiency in treating cancer.
Innovation Solution
The use of meditope technology to 'snap' on antibody fragments to engineered T cells, replacing the scFv with a cQFD meditope to create universal CARs, allowing for antigen-binding domains that can target various cancer antigens without the need for gene modification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If traditional CAR T-cell therapy is used to target specific cancer antigens, then T cells can effectively kill cancer cells with high specificity, but new genes must be created for each target antigen which limits versatility and increases complexity
Solution Approach 1:
The patent creates a universal CAR T-cell platform where a single meditope-enabled CAR construct can bind to multiple different antibody fragments (Fab regions) through the meditope tag. This allows one T-cell line to target various cancer antigens by simply exchanging the antibody fragment component, eliminating the need to create new genes for each target antigen while maintaining high target specificity.
Solution Approach 2:
The patent divides the targeting mechanism into separate functional modules: (1) the meditope-enabled CAR expressed in T cells that provides the universal binding interface, and (2) interchangeable antibody fragment components that provide antigen specificity. This segmentation allows independent optimization of each module and enables rapid reconfiguration by combining different antibody fragments with the universal CAR platform.
2Adaptability or versatility
If meditope technology is used to snap on antibody fragments to engineered T cells, then versatility across different cancer types is improved, but the structural complexity of the CAR construct increases
Solution Approach 1:
The patent introduces the meditope tag as an intermediary element that mediates the interaction between the CAR construct and antibody fragments. The meditope is a small peptide tag incorporated into the CAR that specifically binds to engineered antibody fragments containing the corresponding meditope recognition site. This intermediary simplifies the overall structure by providing a standardized, small-molecular-weight binding interface rather than requiring large protein-protein interaction domains.
3Adaptability or versatility
If scFv is replaced with cQFD meditope in CAR constructs, then the ability to bind various antibody fragments is improved, but the traditional antigen-binding domain functionality must be maintained
Solution Approach 1:
The patent merges two distinct functions into a single CAR construct: (1) the cQFD meditope domain that provides versatile binding to engineered antibody fragments, and (2) the traditional antigen-binding domain (such as CD3ζ signaling domain) that maintains reliable antigen recognition and T-cell activation. Both functions operate simultaneously within the same CAR molecule, ensuring that versatility in antibody fragment binding does not compromise antigen-binding efficacy.
Data Source
AI summary
Provided herein are compositions which exhibit novel therapeutic capabilities and allow to reduce the off-target effect of therapeutic antibodies. The compositions include recombinant proteins that if expressed by a T cell can efficiently recruit therapeutic antibodies to their site of action.